Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up

Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up

The tumor necrosis factor-α (TNF-α) antagonists infliximab, adalimumab, and etanercept have been approved for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Manifestations of demyelinating disease have been rep...

Full description

Bibliographic Details
Main Authors: Sandra C. Signore, Birka Brauns, Gunther Schütze, Christoph P. Dohm, Mathias Bähr, Rotraut Mössner, Pawel Kermer
Format: Article
Language:English
Published: Karger Publishers 2018-01-01
Series:Case Reports in Neurology
Subjects:
Infliximab
Chronic inflammatory central nervous system disease
Peroneal nerve injury
Treatment-refractory psoriasis
Online Access:https://www.karger.com/Article/FullText/485499

Internet

https://www.karger.com/Article/FullText/485499

Similar Items